Tom Gayner’s Merck MRK Stock Holding History

Tom Gayner’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-5,869	Closed	-$305K	–	145
2018 Q1	$305K	Hold	5,869	–	–	0.01%	134
2017 Q4	$315K	Hold	5,869	–	–	0.01%	135
2017 Q3	$359K	Hold	5,869	–	–	0.01%	135
2017 Q2	$359K	Hold	5,869	–	–	0.01%	133
2017 Q1	$356K	Hold	5,869	–	–	0.01%	130
2016 Q4	$330K	Hold	5,869	–	–	0.01%	129
2016 Q3	$349K	Hold	5,869	–	–	0.01%	125
2016 Q2	$323K	Buy	+5,869	New	+$312K	0.01%	127

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Tom Gayner's MRK Position: Q2 2018 in Review

Tom Gayner sold out of Merck (MRK) in Q2 2018, closing a stake of 5,869 shares — an estimated $305K sold.

Tom Gayner first reported a position in MRK in Q2 2016 and held it in 8 quarters. The position peaked at $359K in Q3 2017. 2,018 funds tracked by Wall St. Rank hold MRK as of Q2 2018.

Tom Gayner reported no remaining Merck position as of Q2 2018 after selling out during the quarter.
Tom Gayner sold 5,869 Merck shares in Q2 2018, an estimated $305K.
Tom Gayner first reported a position in Merck in Q2 2016 and held it in 8 quarters.
Tom Gayner's Merck position peaked at $359K in Q3 2017.
2,018 funds tracked by Wall St. Rank held Merck as of Q2 2018.

Based on Markel Group's 13F filing for Q2 2018, filed 3 Aug 2018.